CCP
TRML

Clough Capital Partners’s Tourmaline Bio TRML Stock Holding History

Clough Capital Partners’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,360
Closed -$494K – 144
2021
Q2 		$494K Buy
+3,360
New +$515K 0.03% 119

Other funds holding TRML

Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Clough Capital Partners's TRML Position: Q3 2021 in Review

Clough Capital Partners sold out of Tourmaline Bio (TRML) in Q3 2021, closing a stake of 3,360 shares — an estimated $494K sold.

Clough Capital Partners first reported a position in TRML in Q2 2021 and held it in 1 quarter. The position peaked at $494K in Q2 2021. 48 funds tracked by Wall St. Rank hold TRML as of Q3 2021.

  • Clough Capital Partners reported no remaining Tourmaline Bio position as of Q3 2021 after selling out during the quarter.
  • Clough Capital Partners sold 3,360 Tourmaline Bio shares in Q3 2021, an estimated $494K.
  • Clough Capital Partners first reported a position in Tourmaline Bio in Q2 2021 and held it in 1 quarter.
  • Clough Capital Partners's Tourmaline Bio position peaked at $494K in Q2 2021.
  • 48 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2021.

Based on Clough Capital Partners's 13F filing for Q3 2021, filed 15 Nov 2021.